Transcription-based drug repurposing for COVID-19

We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Killick, Richard, Ballard, Clive, Doherty, Patrick, Williams, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518800/
https://www.ncbi.nlm.nih.gov/pubmed/32987033
http://dx.doi.org/10.1016/j.virusres.2020.198176
_version_ 1783587455330418688
author Killick, Richard
Ballard, Clive
Doherty, Patrick
Williams, Gareth
author_facet Killick, Richard
Ballard, Clive
Doherty, Patrick
Williams, Gareth
author_sort Killick, Richard
collection PubMed
description We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.
format Online
Article
Text
id pubmed-7518800
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75188002020-09-28 Transcription-based drug repurposing for COVID-19 Killick, Richard Ballard, Clive Doherty, Patrick Williams, Gareth Virus Res Short Communication We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication. Published by Elsevier B.V. 2020-12 2020-09-25 /pmc/articles/PMC7518800/ /pubmed/32987033 http://dx.doi.org/10.1016/j.virusres.2020.198176 Text en © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Killick, Richard
Ballard, Clive
Doherty, Patrick
Williams, Gareth
Transcription-based drug repurposing for COVID-19
title Transcription-based drug repurposing for COVID-19
title_full Transcription-based drug repurposing for COVID-19
title_fullStr Transcription-based drug repurposing for COVID-19
title_full_unstemmed Transcription-based drug repurposing for COVID-19
title_short Transcription-based drug repurposing for COVID-19
title_sort transcription-based drug repurposing for covid-19
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518800/
https://www.ncbi.nlm.nih.gov/pubmed/32987033
http://dx.doi.org/10.1016/j.virusres.2020.198176
work_keys_str_mv AT killickrichard transcriptionbaseddrugrepurposingforcovid19
AT ballardclive transcriptionbaseddrugrepurposingforcovid19
AT dohertypatrick transcriptionbaseddrugrepurposingforcovid19
AT williamsgareth transcriptionbaseddrugrepurposingforcovid19

Ejemplares similares